Search This Blog

Friday, January 31, 2020

Celgene withdraws enasidenib application in Europe

Bristol-Myers Squibb (NYSE:BMY) unit Celgene (NASDAQ:CELG) has withdrawn its marketing application in Europe for Idhifa (enasidenib) for the treatment of adults with acute myeloid leukemia (AML).
The company took action after determining that it could not fully address EMA objections. Specifically, the agency concluded that the data supporting the application were insufficient to prove efficacy.
https://seekingalpha.com/news/3536875-celgene-withdraws-enasidenib-application-in-europe

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.